» Articles » PMID: 33951289

Priming Human Adipose-derived Mesenchymal Stem Cells for Corneal Surface Regeneration

Overview
Journal J Cell Mol Med
Date 2021 May 5
PMID 33951289
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Limbal stem cells (LSC) maintain the transparency of the corneal epithelium. Chemical burns lead the loss of LSC inducing an up-regulation of pro-inflammatory and pro-angiogenic factors, triggering corneal neovascularization and blindness. Adipose tissue-derived mesenchymal stem cells (AT-MSC) have shown promise in animal models to treat LSC deficiency (LSCD), but there are not studies showing their efficacy when primed with different media before transplantation. We cultured AT-MSC with standard medium and media used to culture LSC for clinical application. We demonstrated that different media changed the AT-MSC paracrine secretion showing different paracrine effector functions in an in vivo model of chemical burn and in response to a novel in vitro model of corneal inflammation by alkali induction. Treatment of LSCD with AT-MSC changed the angiogenic and inflammatory cytokine profile of mice corneas. AT-MSC cultured with the medium that improved their cytokine secretion, enhanced the anti-angiogenic and anti-inflammatory profile of the treated corneas. Those corneas also presented better outcome in terms of corneal transparency, neovascularization and histologic reconstruction. Priming human AT-MSC with LSC specific medium can potentiate their ability to improve corneal wound healing, decrease neovascularization and inflammation modulating paracrine effector functions in an in vivo optimized rat model of LSCD.

Citing Articles

Biomedical Application of MSCs in Corneal Regeneration and Repair.

De Miguel M, Cadenas-Martin M, Stokking M, Martin-Gonzalez A Int J Mol Sci. 2025; 26(2).

PMID: 39859409 PMC: 11766311. DOI: 10.3390/ijms26020695.


The Role of Mesenchymal Stem Cells for Corneal Endothelial Regeneration: A Systematic Review.

Siska S, Wiratnaya I, Bakta I, Jawi I, Widiana I, Yuliawati P Rambam Maimonides Med J. 2024; 15(4).

PMID: 39503547 PMC: 11524423. DOI: 10.5041/RMMJ.10531.


Molecular and Cellular Mechanisms of the Therapeutic Effect of Mesenchymal Stem Cells and Extracellular Vesicles in Corneal Regeneration.

Kobal N, Marzidovsek M, Schollmayer P, Malicev E, Hawlina M, Marzidovsek Z Int J Mol Sci. 2024; 25(20).

PMID: 39456906 PMC: 11507649. DOI: 10.3390/ijms252011121.


Targeting limbal epithelial stem cells: master conductors of corneal epithelial regeneration from the bench to multilevel theranostics.

Li S, Sun H, Chen L, Fu Y J Transl Med. 2024; 22(1):794.

PMID: 39198892 PMC: 11350997. DOI: 10.1186/s12967-024-05603-y.


Licensing effects of inflammatory factors and TLR ligands on the regenerative capacity of adipose-derived mesenchymal stem cells.

Szucs D, Monostori T, Miklos V, Pahi Z, Poliska S, Kemeny L Front Cell Dev Biol. 2024; 12:1367242.

PMID: 38606318 PMC: 11007080. DOI: 10.3389/fcell.2024.1367242.


References
1.
Jiang D, Xiong G, Feng H, Zhang Z, Chen P, Yan B . Donation of mitochondria by iPSC-derived mesenchymal stem cells protects retinal ganglion cells against mitochondrial complex I defect-induced degeneration. Theranostics. 2019; 9(8):2395-2410. PMC: 6531297. DOI: 10.7150/thno.29422. View

2.
Coulson-Thomas V, Coulson-Thomas Y, Gesteira T, Kao W . Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System. Ocul Surf. 2016; 14(2):121-34. PMC: 4842329. DOI: 10.1016/j.jtos.2015.11.004. View

3.
Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J . Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2005; 80(3):267-74. DOI: 10.1016/j.yexmp.2005.07.004. View

4.
Aggarwal S, Pittenger M . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004; 105(4):1815-22. DOI: 10.1182/blood-2004-04-1559. View

5.
Li P, Guo X . A review: therapeutic potential of adipose-derived stem cells in cutaneous wound healing and regeneration. Stem Cell Res Ther. 2018; 9(1):302. PMC: 6225584. DOI: 10.1186/s13287-018-1044-5. View